SB
SPRY icon

Samsara BioCapital’s ARS Pharmaceuticals SPRY Stock Holding History

Samsara BioCapital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,000
Closed -$1.16K – 50
2020
Q4 		$1.16K Buy
+25,000
New +$835K 0.12% 38

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Samsara BioCapital's SPRY Position: Q1 2021 in Review

Samsara BioCapital sold out of ARS Pharmaceuticals (SPRY) in Q1 2021, closing a stake of 25,000 shares — an estimated $1.16K sold.

Samsara BioCapital first reported a position in SPRY in Q4 2020 and held it in 1 quarter. The position peaked at $1.16K in Q4 2020. 68 funds tracked by Wall St. Rank hold SPRY as of Q1 2021.

  • Samsara BioCapital reported no remaining ARS Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Samsara BioCapital sold 25,000 ARS Pharmaceuticals shares in Q1 2021, an estimated $1.16K.
  • Samsara BioCapital first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Samsara BioCapital's ARS Pharmaceuticals position peaked at $1.16K in Q4 2020.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2021.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.